Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735212 | 0.79 | KAT2B (0.38) | HRH3KDM4ETNFKAT2B | |
| SCHEMBL6736136 | 0.74 | TSHR (0.46) | TSHRALDH1A1LMNAPOLBTNF | |
| SCHEMBL7068440 | 0.66 | KAT2B (0.43) | TSHRALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL15783530 | 0.65 | TSHR (0.36) | HRH3TSHRALDH1A1LMNAPOLB | |
| SCHEMBL29700358 | 0.64 | LMNA (0.49) | HRH3TSHRALDH1A1LMNAPOLB | |
| SCHEMBL674463 | 0.64 | LMNA (0.49) | HRH3TSHRALDH1A1LMNAPOLB | |
| SCHEMBL8957048 | 0.64 | LMNA (0.49) | HRH3TSHRALDH1A1LMNAPOLB | |
| SCHEMBL23147045 | 0.64 | ALDH1A1 (0.40) | HRH3TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL10648648 | 0.64 | KMT2A (0.48) | TSHRALDH1A1LMNAKAT2BMAPT | |
| SCHEMBL26097101 | 0.64 | TSHR (0.54) | TSHRALDH1A1LMNAPOLBTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885TSHR 2768/4885ALDH1A1 569/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885TSHR 2768/4885ALDH1A1 569/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885TSHR 2768/4885ALDH1A1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.